​
​

ALX Oncology (ALXO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALXO Stock Forecast

ALX Oncology stock forecast is as follows: an average price target of $24.50 (represents a 1799.22% upside from ALXO’s last price of $1.29) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ALXO Price Target

The average price target for ALX Oncology (ALXO) is $24.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $14.00. This represents a potential 1799.22% upside from ALXO's last price of $1.29.

ALXO Analyst Ratings

Buy

According to 5 Wall Street analysts, ALX Oncology's rating consensus is 'Buy'. The analyst rating breakdown for ALXO stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ALX Oncology Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2024Colin BristowUBS$25.00$8.82183.29%1837.98%
Jun 03, 2024Christopher RaymondRaymond James$21.00$9.10130.77%1527.91%
Apr 10, 2024Bradley CaninoStifel Nicolaus$14.00$11.8518.14%985.27%
Aug 09, 2022-Credit Suisse$38.00$11.77222.85%2845.74%
Jun 13, 2022Bradley CaninoStifel Nicolaus$16.00$6.79135.81%1140.31%
Row per page
Go to

The latest ALX Oncology stock forecast, released on Jun 10, 2024 by Colin Bristow from UBS, set a price target of $25.00, which represents a 183.29% increase from the stock price at the time of the forecast ($8.82), and a 1837.98% increase from ALXO last price ($1.29).

ALX Oncology Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$20.00
Last Closing Price$1.29$1.29$1.29
Upside/Downside-100.00%-100.00%1450.39%

In the current month, the average price target of ALX Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ALX Oncology's last price of $1.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2024UBSBuyBuyHold
Jun 03, 2024Piper SandlerOverweightOverweightHold
May 10, 2024H.C. WainwrightBuyBuyHold
Dec 08, 2023Jefferies-BuyUpgrade
Aug 09, 2022Credit SuisseOutperformOutperformHold
May 19, 2022Piper SandlerOverweightOverweightHold
Row per page
Go to

ALX Oncology's last stock rating was published by UBS on Jun 10, 2024. The company gave ALXO a "Buy" rating, the same as its previous rate.

ALX Oncology Financial Forecast

ALX Oncology Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue---------$1.18-$527.00K
Avg Forecast-------$105.40K$131.00K$-36.40K$250.00K$550.00K
High Forecast-------$105.40K$131.00K$-36.40K$250.00K$550.00K
Low Forecast-------$105.40K$131.00K$-36.40K$250.00K$550.00K
# Analysts-------11-11
Surprise %----------0.00%-0.96%

ALX Oncology's average Quarter revenue forecast for Mar 21 based on 1 analysts is $131.00K, with a low forecast of $131.00K, and a high forecast of $131.00K. ALXO's average Quarter revenue forecast represents a 11082810.32% increase compared to the company's last Quarter revenue of $1.18 (Dec 20).

ALX Oncology EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts-------11-11
EBITDA-------$-16.27M$-14.18M$-18.44M$-9.91M$-11.01M
Avg Forecast-------$21.08K$-16.25M$-7.28K$50.00K$-112.63M
High Forecast-------$21.08K$-13.00M$-7.28K$50.00K$-90.11M
Low Forecast-------$21.08K$-19.50M$-7.28K$50.00K$-135.16M
Surprise %--------771.62%0.87%2532.77%-198.30%0.10%

undefined analysts predict ALXO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ALX Oncology's previous annual EBITDA (undefined) of $NaN.

ALX Oncology Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts-------11-11
Net Income-------$-16.27M$-14.19M$-18.77M$-10.18M$-11.33M
Avg Forecast$-34.15M$-33.51M$-34.36M$-37.10M$-35.83M$-41.10M$-38.79M$-22.62M$-16.26M$-17.97M$-17.93M$-115.89M
High Forecast$-34.15M$-33.51M$-34.36M$-28.80M$-29.60M$-41.10M$-38.79M$-22.62M$-13.01M$-17.97M$-17.93M$-92.71M
Low Forecast$-34.15M$-33.51M$-34.36M$-45.39M$-42.06M$-41.10M$-38.79M$-22.62M$-19.51M$-17.97M$-17.93M$-139.06M
Surprise %-------0.72%0.87%1.04%0.57%0.10%

ALX Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALXO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

ALX Oncology SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts-------11-11
SG&A-------$5.09M$4.36M$5.68M$4.48M$3.17M
Avg Forecast-------$341.91K$424.95K$-118.08K$810.98K$1.78M
High Forecast-------$341.91K$424.95K$-118.08K$810.98K$1.78M
Low Forecast-------$341.91K$424.95K$-118.08K$810.98K$1.78M
Surprise %-------14.88%10.26%-48.13%5.53%1.78%

ALX Oncology's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALXO last annual SG&A of $5.09M (Jun 21).

ALX Oncology EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts-------11-11
EPS-------$-0.40$-0.35$-0.50$-0.36$-0.40
Avg Forecast$-0.65$-0.64$-0.65$-0.70$-0.68$-0.78$-0.75$-0.44$-0.41$-0.35$-0.35$-0.32
High Forecast$-0.65$-0.64$-0.65$-0.55$-0.56$-0.78$-0.75$-0.44$-0.41$-0.35$-0.35$-0.32
Low Forecast$-0.65$-0.64$-0.65$-0.86$-0.80$-0.78$-0.75$-0.44$-0.41$-0.35$-0.35$-0.32
Surprise %-------0.92%0.85%1.44%1.04%1.26%

According to undefined Wall Street analysts, ALX Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALXO previous annual EPS of $NaN (undefined).

ALX Oncology Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VIRXViracta Therapeutics$0.15$8.005233.33%Buy
BCELAtreca$0.09$4.004344.44%Buy
ALXOALX Oncology$1.29$24.501799.22%Buy
IPSCCentury Therapeutics$1.24$15.001109.68%Buy
PASGPassage Bio$0.54$6.001011.11%Buy
CABACabaletta Bio$1.87$16.33773.26%Buy
BDTXBlack Diamond Therapeutics$2.43$14.75507.00%Buy
AVTEAerovate Therapeutics$2.61$13.00398.08%Hold
BCABBioAtla$1.39$5.00259.71%Buy
BMEABiomea Fusion$6.38$22.75256.58%Buy
CCCCC4 Therapeutics$4.01$13.50236.66%Buy
EYPTEyePoint Pharmaceuticals$8.35$26.00211.38%Buy
IMTXImmatics$7.58$22.00190.24%Buy
STOKStoke Therapeutics$11.27$30.60171.52%Buy
CGEMCullinan Oncology$12.22$31.50157.77%Buy
MLYSMineralys Therapeutics$11.87$30.00152.74%Buy
DYNDyne Therapeutics$29.73$43.8847.60%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
CRNXCrinetics Pharmaceuticals$57.03$70.1422.99%Buy
RVMDRevolution Medicines, Inc. Warrant$56.78$60.636.78%Buy

ALXO Forecast FAQ

Is ALX Oncology a good buy?

Yes, according to 5 Wall Street analysts, ALX Oncology (ALXO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ALXO's total ratings.

What is ALXO's price target?

ALX Oncology (ALXO) average price target is $24.5 with a range of $14 to $38, implying a 1799.22% from its last price of $1.29. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ALX Oncology stock go up soon?

According to Wall Street analysts' prediction for ALXO stock, the company can go up by 1799.22% (from the last price of $1.29 to the average price target of $24.5), up by 2845.74% based on the highest stock price target, and up by 985.27% based on the lowest stock price target.

Can ALX Oncology stock reach $2?

ALXO's average twelve months analyst stock price target of $24.5 supports the claim that ALX Oncology can reach $2 in the near future.

What are ALX Oncology's analysts' financial forecasts?

ALX Oncology's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-116M (high $-109M, low $-122M), average SG&A $0 (high $0, low $0), and average EPS is $-2.208 (high $-2.09, low $-2.327). ALXO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-139M (high $-131M, low $-147M), average SG&A $0 (high $0, low $0), and average EPS is $-2.64 (high $-2.483, low $-2.797).

Did the ALXO's actual financial results beat the analysts' financial forecasts?

Based on ALX Oncology's last annual report (Dec 2020), the company's revenue was $1.18M, beating the average analysts forecast of $763.6K by 54.79%. Apple's EBITDA was $-44.067M, missing the average prediction of $-113M by -60.86%. The company's net income was $-45.74M, missing the average estimation of $-152M by -69.87%. Apple's SG&A was $14.81M, beating the average forecast of $2.48M by 497.85%. Lastly, the company's EPS was $-2.47, beating the average prediction of $-1.013 by 143.79%. In terms of the last quarterly report (Dec 2020), ALX Oncology's revenue was $1.18, missing the average analysts' forecast of $-36.4K by -100.00%. The company's EBITDA was $-18.436M, beating the average prediction of $-7.279K by 253176.55%. ALX Oncology's net income was $-18.774M, beating the average estimation of $-17.968M by 4.48%. The company's SG&A was $5.68M, missing the average forecast of $-118K by -4912.92%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.347 by 44.23%